Clinical And Cognitive ERP Research On Depression(Mild、Moderate) Of Hepatic Depression Syndrome

Objective:1To learn the prevalence in Depression (mild、moderate) of Hepatic DepressionSyndrome among college students, and to Select a part of depression patients with clinicalinterventions;2To observe intervention effect of Shugan granules on depression patients of HepaticDepression Syndrome and to explore clinical mechanisms,providing data support andclinical evidence for the regulation mechanisms of “liver controlling dispersion andregulating emotions”;3To observe the cognitive ERP features in patients with depression, providing nerveelectrophysiology and laboratory data evidence for the theory of “liver controllingdispersion and regulating emotions”。Methods:1Using cross-sectional epidemiological survey methods. Volunteers fill out the"spiritual oxygen bar" scale, and investigators analyze the data retrieved. Two chiefphysician of clinical psychology conducted diagnosis and gave psychological counseling toSuspicious patients with depression.Patients adhered to the voluntary principle and theirprivacy were respected.A part of depression patients were given clinical interventions withChinese herbs2Using a randomized, double-blind method.30patients of treatment group weregiven Shugan granules and fluoxetine capsules;30patients of the control group weregiven fluoxetine capsules and mimetic Shugan granules. Observation items include: beforeand after treatment in patients with signs and symptoms, Zung’s Self-Rating DepressionScale (SDS), Hamilton Depression Scale,Gan Qi Stagnation Rating Scale, neuroendocrine indicators, electrocardiogram, liver function and kidney function. Treatment for six weeks.3Using visual Oddball experiments form,16cases of college students with depressionwere taken as treatment group and another16cases of healthy college students taken ascontrol group. Observing cognitive ERP features of two groups, analyzing changes of P300amplitude and latency in different electrode sites.Neuroscan4.5analysis system with40-lead EEG acquisition were used to record EEG waveforms.E-prime2.0stimuluspresentation systems were used to collect behavioral data. SPSS17.0were adopted for dataanalysis.Results:1The point prevalence in Depression (mild、 moderate) of Hepatic DepressionSyndrome among college students was1.68%.The proportion of women with depressionwere significantly higher than males.SDS scale is not affected by gender limitations inscreening for depression.When screening for depression, items1and19of SDS can serveas an important role.Significant statistical difference was existed between suspiciouspatients who were surveyed by SDS and those final diagnosed depression (mild、moderate)of Hepatic Depression Syndrome (P <0.01).2Comparison between two groups of patients with depression were no significantdifferences (P>0.05) in the treatment of the main symptoms and signs. The reduced rate ofHamilton Scale between two groups was also no significant difference (P>0.05). Aftertreatment, individual symptom such as depression, reduce interest between the treatmentgroup and the control group had significant statistical differences(P<0.05). Two groups ofpatients had significant statistical difference in gan qi stagnation scale score (p<0.05).HAMD scale score between two groups had not significant statistical difference(p>0.05).SDS scale score had significant statistical differences(P<0.05). Difference between theneuroendocrine indicators had no statistical difference between treatment group andcontrol group after treatment(P>0.05). Before and after treatment, liver and kidneyfunction and ECG of both groups of patients were within the normal range. During thetreatment,two groups had no adverse events.3In the30scalp electrodes, the P300waveform of F4, F3, FZ, P3, P, and Pz isparticularly evident.Electrode P300amplitude in point such as FZ,FP1and FP2located infrontal area of depression patients significantly increased and had a significant differenceafter treatment(P<0.05). Although there was no significant statistical significance in P300latency period of the FP1and FP2after treatment (P>0.05).The cognitive function of frontal lobe in depression patients may have changed.Conclusion:1The point prevalence in Depression (mild、 moderate) of Hepatic DepressionSyndrome among college students was1.68%.The proportion of women with depressionwere significantly higher than males.SDS scale is not affected by gender limitations inscreening for depression.When screening for depression, items1and19of SDS can serveas an important role.2Both groups can improve the patient’s symptoms and signs. Shugan granules cansignificantly improve the patient’s individual symptoms: depression, reduce interest forexample. SDS scales can be used as a reference to determine the clinical efficacy. Theclinical significance of Neuroendocrine indicators need to be further studied to verify theefficacy of the mechanism.3The cognitive function of frontal lobe in depression (mild、moderate) of HepaticDepression Syndrome may have changed.P300can be used as the reference for clinicalefficacy judged of Shugan granules, and may provide electrophysiological evidences forthe theory of “liver controlling dispersion and regulating emotions”.